A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies
Latest Information Update: 29 Sep 2024
At a glance
- Drugs Pembrolizumab+vibostolimab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 13 Sep 2024 This trial has been completed in Hungary, according to the European Clinical Trials Database record.
- 05 Sep 2024 Planned End Date changed from 29 Aug 2024 to 10 Dec 2024.
- 05 Sep 2024 Planned primary completion date changed from 29 Aug 2024 to 10 Dec 2024.